A research paper recently published on Oncotarget showed that one type of breast cancer, known as triple negative breast cancer (TNBC) can be treated using hormone therapy. According to the paper, the breast cancer cells which can be treated using hormone therapy are those that express estrogen receptor beta (ERβ), a type of protein. The results of the study might also make it possible for a drug to treat this type of breast cancer to be developed.
TNBC accounts for 15% of all diagnosed cases of breast cancer. It is an aggressive cancer which lacks some receptor proteins, making it difficult to treat using targeted hormone therapy, which is what is mostly used to treat other types of breast cancer. But the presence of ERβ cells in these cancer cells makes it possible for their growth to be slowed down by administering the patients with estrogen. This is great news for breast cancer patients.
IntraGen announced that they recently published a paper titled the relationship between cetuximab efficacy and miR-31- 3p expression in Oncotarget. The paper details the results of a clinical trial known as NEW EPOC which analyzed the expression of miR-31-3p in samples of tumors from patients. According to the paper, examining the expression of miR-31-3p in tumors can be used to diagnose patients and this will greatly help with their treatment.
Oncotarget is an online medical journal that publishes research papers on oncology once every week. It was started in 2010, and is known for the reliable information it provides. While it started out as an oncology journal, it now publishes articles on many other subjects including cardiology, neuroscience and pharmacology among others.
Oncotarget has provided a great platform for researchers to publish their findings on various studies. It contributes in a great way to advancements in the treatment of various cancers and other conditions. The two articles on breast cancer and miR-31-3p expression will definitely benefit many cancer patients.